SCHEMBL7123497

SCHEMBL7123497

O=C(N[C@@H]1C[C@H]2CC[C@@H]1N2)c1ccc(Sc2cc(N3CCOCC3)cs2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.38
PBK Q96KB5 1/20 0.36
CHRNA7 P36544 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KDM1A O60341 2/20 0.35
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
KDM1B Q8NB78 2/20 0.35
RCOR1 Q9UKL0 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HDAC8 Q9BY41 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
MAPT P10636 3/20 0.34
ATM Q13315 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7120596 0.85 CHRNA7 (0.36) USP30PBKCHRNA7KDM4EALDH1A1
SCHEMBL7123901 0.84 RIPK2 (0.41) USP30CHRNA7KDM4EALDH1A1KDM1A
SCHEMBL7122345 0.84 USP30 (0.38) USP30CHRNA7KDM4EALDH1A1KDM1A
SCHEMBL7127346 0.83 USP30 (0.38) USP30PBKKDM4EALDH1A1KDM1A
SCHEMBL7113625 0.83 CHRNA7 (0.36) CHRNA7MEN1KMT2A
SCHEMBL7120635 0.82 KDM4E (0.39) USP30CHRNA7KDM4EALDH1A1MAPT
SCHEMBL7125332 0.82 HDAC1 (0.38) USP30PBKCHRNA7MAPTFLT3
SCHEMBL7224240 0.82 F10 (0.35) USP30ALDH1A1MEN1KMT2AMAPT
SCHEMBL7124878 0.81 ADAM17 (0.36) USP30CHRNA7KDM4EALDH1A1MAPT
SCHEMBL7122479 0.81 USP30 (0.39) USP30CHRNA7KDM4EALDH1A1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 USP30 2511/4885PBK 1131/4885CHRNA7 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.